Actovegin

Phase 3Small molecule

Takeda

Actovegin is one of 54 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Arterial Occlusive DiseaseActive, not recruiting

Cognitive ImpairmentPhase 3

Active, not recruiting

Arterial Occlusive DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Provigil

NNuvo Research GmbH

Phase 3

1 4

Xarelto

WWim Janssens

Phase 3

1 5

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 6

Viagra

VViatris Specialty LLC

Phase 3

1 7

Donepezil Hydrochloride

Eisai

Phase 3

3 8

Statins

Sanofi

Phase 3

1 9

Nicorette

Pfizer

Phase 2

2 10

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Arterial Occlusive Disease1 trial

Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Completed· Takeda logo

Takeda·Phase 3·NCT03469349·366 enrolled

Cognitive impairment1 trial

Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

Completed· Takeda logo

Takeda·Phase 3·NCT01582854·503 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Actovegin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Actovegin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Actovegin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Actovegin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Arterial Occlusive Disease1 trial

Cognitive impairment1 trial

References

Drug Info

Quick Facts

Related News